Syndax Pharmaceuticals Q4 2025 Earnings Preview
Source: SeekingAlpha
2026-02-25 17:35:59 ET
More on Syndax Pharmaceuticals
- Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026
- Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Seeking Alpha’s Quant Rating on Syndax Pharmaceuticals
- Historical earnings data for Syndax Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Syndax Pharmaceuticals Q4 2025 Earnings Preview
Syndax Pharmaceuticals Inc.
NASDAQ: SNDX
SNDX Trading
-3.25% G/L:
$23.38 Last:
835,922 Volume:
$24.24 Open:
SNDX Latest News
March 13, 2026 09:29:43 am
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
February 26, 2026 04:01:00 pm
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
SNDX Stock Data
$1,884,313,688
83,351,330
1.17%
104
N/A
Biotechnology & Life Sciences
Healthcare
US
NEW YORK
